Events mediating transformation from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are unknown. We analyzed gene expression data sets generated on the Affymetrix U133 platform from 22 MGUS and 101 MM patients using gene-set enrichment analysis. Genes overexpressed in MM were enriched for cell cycle, proliferation and MYC activation gene sets. Upon dissecting the relationship between MYC and cell-cycle gene sets, we identified and validated an MYC activation signature dissociated from proliferation. Applying this signature, MYC is activated in 67% of myeloma, but not in MGUS. This was further confirmed by immunohistochemistry (IHC) using membrane CD138 and nuclear MYC double staining. We also showed that almost all tumors with RAS mutations expressed the MYC activation signature, and multiple mechanisms may be involved in activating MYC. MYC activation, whether assessed by geneexpression signature or IHC, is associated with hyperdiploid MM and shorter survival even in tumors that are not proliferative. Bortezomib treatment is able to overcome the survival disadvantage in patients with MYC activation.
Introduction
Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of neoplastic plasma cells that usually secrete monoclonal proteins. Recent studies have shown that most, if not all patients with myeloma, have a preceding monoclonal gammopathy of undetermined significance phase (MGUS). 1, 2 The primary genetic events involved in disease initiation have been well established in myeloma. Translocations involving maf genes, t(4;14), t (11;14) and hyperdiploidy, with its typical pattern of trisomies of chromosome 3, 5, 7, 9, 11, 15, 19, 21, are present in about 90% of all myeloma. 3 These abnormalities are already present in MGUS, often times in patients without transformation to MM for many years. [4] [5] [6] Large-scale epidemiological studies showed that MGUS progress to MM at the rate of 1% per year. 7 These data suggest that secondary or cooperating genetic events are probably required for MGUS to MM transition. However, these secondary genetic events have not been identified. The best characterized genetic difference between MGUS and MM is RAS mutations, which is extremely rare in MGUS and present in about 20-30% of newly diagnosed MM. 8, 9 An initial gene expression analysis showed that the expression profile of MM and MGUS is very similar. 10 A more recent analysis using a denser chip and larger number of patients identified some genes that are differentially expressed, but the functional implications of these genes are unknown. 11 In this study, we derived and validated an MYC activation signature that is dissociated from cell cycle/proliferation and showed that this signature is activated in about two-thirds of MM but not MGUS. In addition, MYC activation is associated with unique genetic subtypes, is functionally relevant and identifies patients with poorer prognosis, who respond better to bortezomib and have improved outcome compared with dexamethasone.
Materials and methods

Primary gene expression data set
Gene expression was performed on CD138 þ -selected bone marrow cells using the Affymetrix U133A chip from 15 healthy donors, 22 MGUS and 101MM from the Mayo Clinic (geneexpression profiling data are available from GEO, accession no. GSE6477). RNA isolation, purification and microarray hybridization have previously been reported. 12 Samples were collected after informed consent was obtained in accordance with the Declaration of Helsinki, and the study was approved by the Mayo Clinic Institutional Review Board.
Gene expression analysis
Gene expression intensity values were generated using the Affymetrix MAS 5.0. software, median-centered, and analyzed using GeneSpring 7.3.1 (Agilent Technologies, Palo Alto, CA, USA). To examine the biological and functional relevance of the differentially expressed genes between MM and MGUS, we performed gene set enrichment analysis (GSEA), which has been described elsewhere. 13 To define the enrichment of MYC pathway genes and the other correlated pathways or functional program at the individual sample level, we made a modification to the GSEA algorithm called individual sample GSEA that allows us to generate enrichment scores for different gene sets for individual samples. Using a method analogous to the leading edge analysis, several core gene signatures were derived from highly correlated gene sets that may represent similar biological processes or pathways. We further summarized the expression of genes constituting the core gene signatures into a single value using iPASA (see Supplementary Methods for details) so that each signature is represented by a number on a continuous scale.
Immunohistochemistry
The C-MYC and CD138 IHC double stain was carried out using the BondMax Autostainer (Leica Microsystems, Wetzlar, Germany) which utilizes the define polymer technique. A 5-mm tissue section containing the tissue microarrays was placed onto the BondMax Autostainer (Leica Microsystems) with covertile positioned over the slide, which was deparaffinized and hydrated. Heat-induced epitope retrieval was accomplished for C-MYC using ER1 for 20 min. Endogenous peroxidase was blocked using hydrogen peroxide. For detection of C-MYC, we used a new anti-C-MYC antibody that has been validated using control experiments with genetically defined C-MYC expression.
14 The slide was incubated in the first primary antibody C-MYC (Epitomics, Burlingame, CA, USA; clone Y69, 1:50) for 30 mins, followed by incubation in a post-primary 3,3-diaminobenzidine for 10 mins, polymer 3,3-diaminobenzidine for 10 mins, and chromogen 3,3-diaminobenzidine for 10 mins (Bond Polymer Refine detection kit, Leica Microsystems, catalog no. DS9800). Subsequently, heat-induced epitope retrieval was performed for the second primary antibody, CD138, using ER1 for 20 min. This was followed by incubation with the second primary antibody, CD138 (DAKO, Glostrup, Denmark; clone MI 15, 1:100) for 30 mins, application of the post-primary alkaline phosphatase for 20 mins, polymer alkaline phosphatase for 30 mins, and fast red for 20 mins (Bond Polymer AP Red detection kit, Leica Microsystems, catalog no. DS9305). The nuclei were counterstained with hematoxylin and the slide dehydrated, cleared in xylene, and coverslipped. Appropriate positive controls were used. The number of plasma cells expressing C-MYC was counted and scored as a percentage of the total CD138-positive plasma cell population Detection of RAS mutation RAS mutation was detected as previously described. 8 Briefly, PCR primers were designed to amplify DNA segments of K-and N-RAS codon 12, 13 and 61. The radiolabeled amplicons were run through 15% mild-denaturing 0.4 mm polyacrylamide gel for 4 h at 40 W. The gel was dried and placed on a phosphorimager screen for analysis. Abnormal banding patterns were subsequently directly sequenced.
Statistical analysis
The Student's t-test was used for comparison of continuous variables. Categorical variables were compared using the w 2 or Fisher's exact test. The distribution for progression-free survival and overall survival (OS) was estimated using the method of Kaplan and Meier. The log-rank test was used to test for differences in survival between groups. Po0.05 was considered significant.
Results
Derivation and validation of proliferation dissociated MYC signature
We have previously shown that MYC and cell cycle-related gene sets are enriched in MM compared with MGUS. 15 It is unclear whether the enrichment of MYC gene sets are due to greater proliferation of MM cells or implicated actual activation of the MYC pathways. To delineate this, we examined the genes that were enriched in the different MYC gene sets and cell-cycle gene sets using the leading edge analysis tool in GSEA. Although some of the enriched genes in the MYC gene sets were also enriched in the cell-cycle gene sets, there was a cluster of genes that was consistently enriched in the different MYC gene sets but not in cell-cycle/proliferation gene sets (Figure 1a) . These genes are involved in different functions not necessarily related to cell cycle; most of them have been validated as DNA-binding target of MYC and all of them are upregulated by MYC (http:// www.myccancergene.org/, supplementary table 1), suggesting that this will constitute a good gene signature for MYC activation that is dissociated from cell cycle and proliferation.
To further validate this signature, we examined the expression of these genes in two independent data sets, where the objective of the original studies was to overexpress different oncogenes in either mouse fibroblast (GEO Accession GSE3151) (ref. 16 ) or human mammary cell lines (GEO Accession GSE3158) (ref. 17) to identify oncogene-specific gene-expression signatures. Our MYC activation signature was overexpressed in the cell lines transfected with MYC in both data sets but not those cell lines with retinoblastoma gene knocked out or overexpressing E2F, which were also expected to be proliferative. A consistent observation was the expression of this signature in cell lines expressing activating RAS mutation in both data sets. This may suggest a relationship between activating RAS mutations and MYC activation (Figures 1b and c) .
MYC activation signature is expressed in MM but not MGUS
Having defined and validated an MYC activation signature that is dissociated from cell cycle or proliferation, we assessed this signature in human myeloma data set, together with other cell types for comparison: normal B-cells, normal plasma cells, Burkitt's lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. 18 As expected, the signature was expressed highly in Burkitt's lymphoma, which harbors IgH-MYC translocations. The signature was not expressed in normal plasma cells or MGUS but was expressed in about 67% of myeloma (Figure 2a ). When the MYC activation signature was summarized as the MYC activation index (MAI) using the median expression of the genes constituting the signature, the MAI was similar between new MM and relapse MM, but significantly higher than normal plasma cells and MGUS (Po0.001) (Figure 2b ). It was also apparent that some tumors with low proliferation and low expression of MYC also have a high MAI. This suggests that there may be different mechanisms that lead to MYC activation. As we had observed an association between activating RAS mutation and expression of the MYC signature in the different validation data sets, we assessed our patient data set for such an association. Indeed, almost all cases with RAS mutations (there is no difference between the percentages of K-and N-RAS mutations in those with high and low MAI, so both are analyzed together as RAS mutants) had a high MAI, confirming our previous observation. Of note, some MM have very high MYC mRNA expression that are possibly driven by IgH-MYC translocations, but do not have RAS mutations and vice versa (Figure 2c ).
Other pathways enriched in MM compared with MGUS
Using individual sample GSEA and leading edge analysis of correlated gene sets, a number of core signatures were identified. Besides MYC and proliferation, proteasome, tRNA, metabolic pathway and interferon pathway gene sets were also enriched. In addition, there is a close correlation between MYC activation, proliferation, tRNA synthesis, increase proteasome subunits and metabolic activity. On the other hand, a subgroup of MM has mainly enrichment of interferon genes without enrichment of MYC and the other correlated signatures (Figure 3a) . Similar pattern and relation was seen in a separate MM gene-expression profiling data set from UAMS (Supplementary Figure 1 ).
To further investigate the relationship between these pathways, we assessed their expression in the P493-6 cell line model system (GEO Accession GSE 19703) (ref. 19 ) using iPASA. The P493-6 cells were established from primary peripheral blood B cells. 20, 21 This cell line was immortalized by an Epstein-Barr viral genome that was complemented with an Epstein-Barr nuclear antigen-estrogen receptor fusion protein and a tetracycline-repressible MYC transgene. It is therefore possible to manipulate the cells to achieve at least three states of MYC activation. 22 Using this model system, we showed that all of these core signatures except the interferon signature were induced upon MYC activation (Figure 3b ), similar to the pattern observed in the tumors expressing the MYC activation signature in the clinical data sets.
MYC activation and IRF4 activity
A recent study suggests that MM cells are addicted to aberrant IRF4 activation and that IRF4 forms a positive auto-regulatory loop with MYC in MM. 23 When we assess the IRF4 index (calculated from 35 IRF4 target genes. 23 using iPASA) in our data set, MM with high MAI have higher IRF4 Index (mean ± s.d., 2.43 ± 0.29 versus Figure 1 Derivation and validation of MYC signature dissociated from cell cycle. (a) Leading edge analysis of enriched MYC and cell-cycle gene sets identified a set of genes that are consistently enriched (red squares) across the different MYC gene sets (in black box) but not in the cell-cycle gene sets. This set of genes constitutes our MYC signature that is dissociated from cell cycle and proliferation. In the grid, the columns represent genes that constitute the main enrichments (leading edge genes) in the different gene sets (row). We then validated this signature in a (b) mouse fibroblast and (c) human mammary cell line gene expression data set. In the heat maps, each row represents a gene and each column a sample. Red represents upregulation and blue downregulation of the respective genes.
1.14±0.23, P ¼ 0.005). This provides further evidence that the MAI is identifying functionally relevant MYC activation.
MYC activation and the NF-kB pathway
The activity of the NF-kB pathway can be modulated by MYC and vice versa. [24] [25] [26] [27] Indeed, the tumors with MYC activation (higher MAI) had lower expression of NF-kB gene signature (mean NF-kB Index, calculated as median expression of genes constituting the NF-kB signature, 0.94±0.6 versus 1.35±0.9 arbitrary units, t-test P ¼ 0.01). This relation was also seen upon modulation of MYC expression in the P493-6 cell line system (Figure 3b ).
MYC staining on IHC correlates with MYC activation signature
Using double staining for surface CD138 and nuclear MYC by IHC in 48MM cases (36 newly diagnosed and 12 relapse) and 8 MGUS (Figure 4) , MYC activation was not detected in MGUS but was identified in 29 out of 48 (60%) MM (P ¼ 0.07). (Table 1 ). This confirms that MYC is activated in a substantial proportion of myeloma but not in the premalignant MGUS.
The percentage of plasma cells with MYC expression is variable. As the distribution of the clinical parameters and the percentage of MYC staining cells was not statistically different between the newly diagnosed and relapse MM in our tissue microarray data set (Supplementary Table 2 ), we grouped them together for analysis. The percentage of MYC-staining cells increases with increasing MAI (Figure 4e ).
Genetic and clinical association of MYC expression
High MYC expression (420% progenitor cells) was significantly more common in tumors with t(4;14), although numbers were small, whereas MYC expression (o20%) was significantly more common in tumors overexpressing CCND1 with or without CCND2 ( Table 1) . As most tumors overexpressing CCND1 are hyperdiploid, we sought to assess whether a high MAI was more common in hyperdiploid MM. Indeed, in the Mayo data set where ploidy was assessed using fluorescence in situ hybridization, MAI41 was found in 81% (46 of 57) of patients with hyperdiploid MM and only 62% (26 of 42) of patients with nonhyperdiploid MM (two-sided Fisher's exact test P-value ¼ 0.04).
We also assessed the association of MAI with clinical parameters, such as plasma cell labeling index, b-2 microglobulin and ISS stage. Patients with MAI41 had higher plasma cell labeling index (median 1 versus 0.25, P ¼ 0.007) and ISS III disease (90% ISS III versus 62% ISSI/II have high MAI, P ¼ 0.03), although there is no difference in b-2 microglobulin level (median 3.89 versus 2.6 mg/dl, P ¼ 0.15).
To investigate the prognostic impact of MYC expression separate from proliferation, we excluded tumors with plasma cell labeling index 41 from the survival analysis. Of the remaining tumors, the plasma cell labeling index of tumors with or without MYC staining was similar (data not shown), yet patients with MYC-expressing tumors still had significantly shorter survival, suggesting that the prognostic impact of MYC expression is independent of proliferation ( Figure 5a ). As there is an association between MYC activation by IHC and the gene expression-based MAI, we assessed the prognostic impact of MAI on survival. Indeed, amongst new diagnosed MM patients, patients with MAI 41 have significantly shorter survival, even when only patients with lowly proliferative tumors were assessed (Figure 5b) .
Recent studies have shown that bortezomib-induced apoptosis is via tumor-specific upregulation of NOXA in an MYCdependent manner. 28 We therefore hypothesize that tumors with MYC activation may be more sensitive to bortezomib treatment. We analyzed a gene expression data set of MM patients entered into a randomized study of bortezomib versus dexamethasone to determine whether there was any relationship between the MAI and outcome with bortezomib. Although single agent bortezomib is rarely used in clinical practice now, this data set is ideal for testing if bortezomib treatment itself may have an impact on MYC-expressing tumors. Consistent with our hypothesis, patients with MAI41 had significantly better response (57% versus 27%, P ¼ 0.03) to bortezomib, whereas response rates to bortezomib and dexamethasone were Figure 2) .
Furthermore, as we had demonstrated similar advantage for bortezomib in patients with low TNF receptor-associated factor 3 (TRAF3) expression previously, 29 we wanted to assess the association between the MAI and TRAF3 level. Treating the normalized expression values as continuous variables, there was no correlation between the MAI and TRAF3 expression levels with a Pearson correlation coefficient of À0.07 (P ¼ 0.38). When we categorized patients into those with MAI41 (MYC activation) and TRAF3o0.6 (TRAF3 inactivation), there was again no association (Fisher's exact P ¼ 0.56). When we assessed the interactions between TRAF3 expression levels and MAI on outcome following Bortezomib treatment compared with dexamethasone, only patients with MAI41 and TRAF3o0.6 had significantly better progression-free survival. In terms of OS, there was a trend towards better OS for patients with MAI41, regardless of TRAF3 level when treated with bortezomib compared with dexamethasone. On the other hand, in patients with MAIp1, even when TRAF3o0.6, the OS was similar between those treated with bortezomib and dexamethasone ( Table 2) .
Discussion
MYC abnormalities have been classically described as a late event in myeloma pathogenesis typically characterized by complex rearrangement involving multiple partners. 30 These types of abnormalities are particularly prevalent in human myeloma cell lines. 31 In contrast, our study suggests that MYC activation is also likely to be an early event in myeloma pathogenesis. Indeed, MYC rearrangement has been reported to be present in about 15% of newly diagnosed myeloma. 32 We see a similar percentage of patients in our data set with very high expression of MYC ('spike' expression), at levels seen in Burkitt's lymphoma, suggesting the presence of IgH-MYC or IgL-MYC translocations. However, this mechanism could not account for most of the cases with MYC activation in our data set.
RAS mutation is present in about 30% of newly diagnosed myeloma and rarely seen in MGUS, suggesting that it is a possible transforming event. 8, 9 In our analysis, the MYC activation signature is present in almost all cases of MM with RAS mutations, regardless of K-or N-RAS mutations, and in the validation data sets when activating mutations of RAS was expressed, suggesting an association between RAS mutations and MYC activation. Our observation is consistent with previous studies showing cooperation between RAS mutations and MYC activation in tumorigenesis and stabilization of the MYC protein by RAS mutants, prolonging the oncogenic activity of MYC. 33, 34 This suggests that RAS mutation is another mechanism leading to MYC activation in MM.
As RAS mutation and 'spiked' expression of MYC occur in a mutually exclusive manner, these aberrations would account for the majority of patients with MYC activation. The remaining mechanisms leading to MYC activation is currently unknown, but may include loss of miRNA that regulate MYC translation [35] [36] [37] or cytokine mediated via IL-6, an important survival factor for MM. 38, 39 Our result is also consistent with a recent transgenic mouse model of myeloma on the basis of sporadic activation of MYC in mice that developed background asymptomatic gammopathy, akin to MGUS. 15 It is also consistent with a recent analysis in a single case where rapid emergence of clonal cells with MYC rearrangements preceded progression from smoldering MM to MM. 40 MYC activation as a cooperating event to cyclin D dysregulation, 41 a universal primary molecular event observed in MGUS, is also mechanistically consistent with the recently described non-transcriptional activity of MYC on DNA replication forks during S phase of the cell cycle. 42 The cooperative deregulation of two different phases of the cell cycle, G 1 M and S phase, may result in transformation into myeloma.
Other pathways may be involved in transformation. In our analysis, we found that proteasome signature, tRNA core signature, cell-cycle signature, metabolic signature and interferon signature were enriched in MM compared with MGUS. In particular, the interferon signature is enriched in samples where the MYC activation signature is not present and vice versa. On the other hand, the other pathways are enriched in a correlated fashion with MYC activation. These results are consistent with published data that MYC activation leads to increased metabolic activity, protein synthesis and cell proliferation, [43] [44] [45] and suppression of interferon response. 26 Furthermore, we showed that myeloma with MYC activation has lower expression of NF-kB pathway signature. It has been shown that MYC activation suppresses NF-kB pathways, 26, 27 and NF-kB is not needed by MYC-induced tumorigenesis, 24, 25 consistent with the lack of expression of NF-kB pathway genes in MYC-driven Burkitt's lymphoma. 46 These correlations were further verified by the gene expression data derived from the P-493-6 cell model upon MYC induction. We also demonstrated a strong association between MYC activation and higher IRF4 activity in the patients, providing further verification of a recent study showing an auto-regulatory loop between IRF4 and MYC in MM. 47 These observations strongly suggest that the predominant signatures seen in the gene expression analysis are due to functionally relevant MYC activation.
In our analysis, MYC activation was associated with protein synthesis (tRNA core signature) and hyperdiploid myeloma. This is consistent with our previous observations from gene expression study that hyperdiploid myeloma overexpress genes related to ribosome biogenesis and protein synthesis. 12 It is intriguing that although the dichotomy between hyperdiploid and non-hyperdiploid myeloma occurs at the earliest stages of pathogenesis, the secondary events also appear to be subtype specific with MYC activation preferred by hyperdiploid MM, whereas chromosome 13 deletion with potentially retinoblastoma gene haploinsufficiency more common in tumors with t(4;14) and translocations involving MAF family genes.
Our analysis also showed that MYC activation detected either using the MYC activation signature or nuclear MYC immunoreactivity by IHC has prognostic importance. Although a previous study shows that MYC rearrangements as detected by fluorescence in situ hybridization lack prognostic relevance, 32 but as mentioned, MYC activation in myeloma is likely mediated by different mechanisms other than genetic rearrangement. Of note, the prognostic relevance of MYC activation also applies to patients with non-proliferative tumors. Although it is not an independent prognostic factor on multivariate analysis (Supplementary Table 3 ), this nevertheless highlights the functional and clinical relevance of MYC activation in MM.
As MYC activation is seen in a substantial number of newly diagnosed MM and is of functional relevance, it may be potentially exploited for therapy. Indeed, we found that MM with MYC activation benefit from bortezomib treatment. Within the limitations of these being a subgroup analysis, these observations are interesting and should be confirmed in other bortezomib gene expression data sets as well as prospective studies. A previous report showed that induction of apoptosis in myeloma cells by bortezomib requires upregulation of NOXA via an MYC-dependent mechanism. 28 In addition, in T-cell lymphoma, bortezomib can downregulate IRF4 and MYC. 48 These are possible reasons for the greater efficacy for bortezomib seen in patients with MYC activation.
An important limitation is that even though we used CD138 þ -sorted cells from MGUS patients, a large amount of these will be the normal component compared with MM, resulting in potential bias. However, the corroboration of geneexpression profiling results by IHC using a double staining method allowing for visualization of individual cells further supports our conclusion.
In summary, MYC activation may be a common transforming event in myeloma. This activation may be mediated by multiple mechanisms, and tumors with MYC activation have a more aggressive course associated with shorter survival. Targeting MYC either directly, 49 or indirectly, through synthetic lethal targets, such as CDK1 (ref. 50) , may be useful therapeutic avenues in myeloma.
Conflict of interest
Chng W-J has received honorariums from Janssen Cilag. Mulligan G is an employee of Millenium Pharmaceuticals, which makes Bortezomib. 
Author Contributions
Chng W-J, designed study, performed analysis and wrote paper; Huang GF, performed gene expression analysis; Chung TH, performed statistical analysis; Ng SB, performed IHC analysis; Gonzalez-Paz N, performed RAS mutation analysis; PriceTroska T, performed RAS mutation analysis; Mulligan G, provided Bortezomib GEP data and analysis; Chesi M, designed study and approved final manuscript; Bergsagel PL, designed study and approved final manuscript; Fonseca R, designed study, provided tissue microarrays and approved final manuscript.
